Science News
from research organizations

Eribulin effective in metastatic breast cancer, researchers find

Date:
January 21, 2015
Source:
Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center
Summary:
While not superior to capecitabine, eribulin is an active and well-tolerated therapy in women with metastatic breast cancer (MBC) receiving this therapy as a first, second, or third line chemotherapy regimen, researchers say.
Share:
FULL STORY

An international research team, led by Dartmouth's Peter A. Kaufman, MD, published findings in the Journal of Clinical Oncology demonstrating that, while not superior to capecitabine, eribulin is an active and well-tolerated therapy in women with metastatic breast cancer (MBC) receiving this therapy as a first, second, or third line chemotherapy regimen. Additionally, these patients had all been previously treated with both an anthracycline and a taxane in either the adjuvant or metastatic setting. This study is the first to address the use of eribulin early in the course of metastatic breast cancer, specifically either the first or second line setting.

"Additionally, it is of great interest that subset analysis suggests that eribulin may be particularly active and effective in triple negative MBC, which is known to be an aggressive subset of breast cancer, and one associated unfortunately with a particularly poor prognosis overall," said Kaufman.

Eribulin has been approved in numerous countries in the third line or latter setting for the treatment of MBC, and is increasingly widely used. It is the only chemotherapeutic agent shown to have a survival benefit for patients with MBC in the third line or latter chemotherapeutic setting. Given previous research findings, and now findings from this large international trial, there has been great interest from oncologists and other clinicians in the potential impact that eribulin might have earlier in the course of MBC.

This phase III randomized trial assigned 1,099 women who had previously been treated with an anthracycline or a taxane to either eribulin or capecitabine as their first, second, or third line chemotherapy for advanced MBC. Stratification factors were human epidermal growth factor receptor-2 (HER2) status and geographic region. Coprimary endpoints were overall survival and progression-free survival.

"While there is not a statistically significant difference in overall survival with eribulin in comparison to capecitabine, the median overall survival seen with eribulin is in fact numerically slightly superior to that of capecitabine," explained Kaufman.

This work supports, and has in part led to, a number of further studies of eribulin in breast cancer. Plans are underway to proceed with pilot adjuvant and neoadjuvant studies, and further studies in MBC. "We are currently developing further studies evaluating the utility of eribulin in treating women with triple negative disease, either alone, or in combination regimens with other therapies," Kaufman commented. "We are additionally planning further research evaluating the role of eribulin in other subtypes of breast cancer, particularly in early stage breast cancer, where this therapy may in fact have a great impact, and improve the cure rate for early stage disease."


Story Source:

Materials provided by Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center. Note: Content may be edited for style and length.


Journal Reference:

  1. P. A. Kaufman, A. Awada, C. Twelves, L. Yelle, E. A. Perez, G. Velikova, M. S. Olivo, Y. He, C. E. Dutcus, J. Cortes. Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. Journal of Clinical Oncology, 2015; DOI: 10.1200/JCO.2013.52.4892

Cite This Page:

Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center. "Eribulin effective in metastatic breast cancer, researchers find." ScienceDaily. ScienceDaily, 21 January 2015. <www.sciencedaily.com/releases/2015/01/150121102954.htm>.
Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center. (2015, January 21). Eribulin effective in metastatic breast cancer, researchers find. ScienceDaily. Retrieved May 27, 2017 from www.sciencedaily.com/releases/2015/01/150121102954.htm
Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center. "Eribulin effective in metastatic breast cancer, researchers find." ScienceDaily. www.sciencedaily.com/releases/2015/01/150121102954.htm (accessed May 27, 2017).

RELATED STORIES